Resectability after two different chemotherapy regimens: results of the first step of a phase II randomised trial in initially resectable stage I – IIIa nonsmall cell lung cancer conducted by the European lung cancer working party P. Lothaire, T. Berghmans, J. J. Lafitte, V. Giner, M. C. Berchier, A. P. Meert, M. Paesmans, P. Mommen, V. Ninane, J. P. Sculier (Brussels, Bruxelles, Belgium; Lille, Hayange, France; Valencia, Spain)
Source: Annual Congress 2003 - Lung cancer staging and combined modality treatment
Session: Lung cancer staging and combined modality treatment Session type: Oral PresentationNumber: 1070
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Lothaire, T. Berghmans, J. J. Lafitte, V. Giner, M. C. Berchier, A. P. Meert, M. Paesmans, P. Mommen, V. Ninane, J. P. Sculier (Brussels, Bruxelles, Belgium; Lille, Hayange, France; Valencia, Spain). Resectability after two different chemotherapy regimens: results of the first step of a phase II randomised trial in initially resectable stage I – IIIa nonsmall cell lung cancer conducted by the European lung cancer working party. Eur Respir J 2003; 22: Suppl. 45, 1070
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003
Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): the MRC LU22/NVALT/EORTC 08012 multi-centre randomised trial Source: Eur Respir J 2007; 30: Suppl. 51, 240s Year: 2007
The big lung trial (BLT): a major randomised trial examining the role of cisplatin-based chemotherapy in all stages of non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002
Phase II study of cisplatin-vinorelbine sequenced by gemcitabine-vinorelbine in patients with unresectable non-small-cell lung cancer (NSCLC): preliminary results Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003
Phase II open-label trial of erlotinib in progressive pretreated advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
Concurrent paclitaxel, carboplatin and radiation therapy for locally advanced non-small cell lung cancer (NSCLC), a phase II multi-institutional trial Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002
Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018
A multicenter phase II study of carboplatin/vinorelbine in advanced non-small cell lung cancer (NSCLC) in elderly patients (GFPC 9902) Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003
Factors predicting complete surgical resection after induction chemotherapy in patients with initially unresectable non-small cell lung cancer (NSCLC) treated in a randomised trial Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003
Main reasons for a low accrual pattern in clinical trials of patients with advanced stage non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Influence of teaching models on skills and knowledge of medical doctors Year: 2008
Phase I trial of lipoplatinÔ and gemcitabine as second line chemotherapy in patients with refractory or resistant advanced non-small-cell lung carcinoma (NSCLC) Source: Eur Respir J 2007; 30: Suppl. 51, 241s Year: 2007
Randomized phase III-trial of platinum- vs. non-platinum-based chemotherapy in stage IV non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 186s Year: 2002
Phase II study of S-1 with patient-reported outcome evaluation in elderly patients with previously untreated advanced non-small cell lung cancer Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017
The selective EGFR tyrosine-kinase inhibitor erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) – a single institution experience of TRUST – a worldwide open label non randomized phase IV trial Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007
A three-arms phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 318s Year: 2001
Biweekly carboplatin-gemcitabine administration in elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study Source: Annual Congress 2007 - Therapy of thoracic malignancies Year: 2007
A study comparing the efficacy, quality of life and toxicity of cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer in the Indian scenario Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients Year: 2011
A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005
International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy? Source: ERJ Open Res, 6 (1) 00159-2019; 10.1183/23120541.00159-2019 Year: 2020
Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non small cell lung cancer (NSCLC) Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003